Single-cell transcriptomic unveils tumor-mediated reprogramming of neutrophils and their unique vulnerability that inhibits metastasis.

Authors

William Putzbach, Maria P Zappia, Ahmed Magdy, Jing Li, Veronique Nogueira, Kevin Lou, Kevan M Shokat, Abul B M M K Islam, Maxim Frolov, Nissim Hay

Published in

Science advances. Volume 12. Issue 29. Pages eaee9308. Jul 17, 2026. Epub Jul 15, 2026.

Abstract

Neutrophils are protumorigenic and prometastatic in tumor-bearing mice. Comprehensive single-cell RNA sequencing analyses on various tissues of naïve and tumor-bearing MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mice unraveled a neutrophil reprogramming process and uncovered a strategy to selectively target reprogrammed neutrophils. Transcriptional reprogramming of neutrophils in tumor-bearing mice is initiated in the bone marrow (BM) by granulocyte colony-stimulating factor (G-CSF). Among the seven neutrophil clusters in the BM, the abundance of one cluster is markedly increased whereas another cluster is diminished in tumor-bearing mice. This reprogramming endures across tissue types including blood, tumor microenvironment, and the metastatic niche in the lungs. Thus, in all tissues tested, neutrophils derived from tumor-bearing mice are transcriptionally distinct from those derived from naïve mice. Among the genes that are markedly induced are members of the Ifitm family. We leverage this facet to selectively target reprogrammed neutrophils through treatment with Rapalink-1-an mTOR (mechanistic target of rapamycin) inhibitor-whose intake is greatly enhanced by IFITM proteins. Reprogrammed neutrophils selectively uptake Rapalink-1, which selectively eradicate them in vivo and normalized the neutrophil-to-lymphocyte ratio in tumor-bearing mice without affecting naïve neutrophils. Last, Rapalink-1 inhibited metastasis of a Rapalink-1-resistant tumor. Thus, Rapalink-1 not only could affect the primary tumor but also selectively eliminates tumor-reprogrammed neutrophils to diminish metastasis.

PMID:
42455928
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.